“Patients have already told the market what they’re willing to pay for a health outcome,” CMT Editor-in-Chief Michael Tetreault said in an interview for this article. “A GLP-1 subscription and a concierge medicine membership now cost about the same, roughly $3,000 a year. The question isn’t whether patients will invest in their health. It’s who earns that investment.”

By Editorial Staff, Concierge Medicine Today, August 2026 (See full list of citations and sources and disclaimers at end of article)

• LISTEN TO THE THE FULL PODCAST

In today’s healthcare marketplace, a patient on a compounded GLP-1 medication and a patient enrolled in a concierge medicine practice are now, on average, spending almost exactly the same amount of money each year.

That single fact should stop the concierge medicine industry mid-stride, because it says something that no amount of internal debate about our own industry’s marketing has managed to say as clearly: patients have already decided they will pay out of pocket for a health outcome. The only open question is which model earns that money, and why.

Today, our team wants to lay out what the marketing and advertising numbers actually show, what they suggest about patient behavior, and where the advertising opening sits for concierge medicine’s marketing strategy going forward.

Please note, this is market and editorial analysis, not medical, legal, financial, or accounting advice, and it does not evaluate the clinical merits of GLP-1 medications, which is a conversation between a patient and their physician. Concierge medicine is not, and should never be marketed as, a treatment alternative to any prescription medication, including GLP-1s. That distinction matters enough that we’re stating it plainly here, before we go any further, and readers should keep it in mind throughout.

That said, let’s unpack the topic.

What patients are actually paying

GLP-1 telehealth pricing is more fragmented than most patients and physicians realize.

A national price index tracking GLP-1 telehealth programs each week found a cash-pay spread of $149 to $448 a month for the same drug class, depending on provider, dose, and whether the medication is compounded or branded (glpchart.com, “GLP-1 Telehealth Price Report 2026,” 2026). Once a patient reaches a therapeutic maintenance dose, typically within two to three months of starting, a detailed cost breakdown from a physician-led telehealth publisher put first-year spending for a mid-tier compounded program at roughly $2,400 to $3,600, and for branded medications like Zepbound purchased through cash-pay channels at $5,400 to $6,600 a year (GLP-1 Telemedicine, “The Real Cost of Telehealth GLP-1 Programs in 2026,” 2026). Full list price for GLP-1 medications without any insurance or telehealth discount runs even higher, from $900 to $1,300 a month according to a 2026 cost guide published by a physician-led weight management clinic (Chronos Body Health & Wellness, “The Real Cost of GLP-1 Weight Loss Medications in 2026,” April 2026).

Concierge medicine, by comparison, carries a lower and more transparent price tag than most people assume. Concierge Medicine Today’s own 2026 Industry Pricing Benchmark, an annual survey of the concierge medicine market, found the median individual membership fee sitting at $3,200 a year, up from $2,950 in 2025, an 8.4 percent year-over-year increase that outpaced general healthcare inflation. The mean is higher, closer to $4,800 a year, pulled upward by a small number of ultra-premium practices. About 70 percent of concierge practices fall in a $1,800 to $5,500 annual range (data cited via Concierge MD Finder, “How Concierge Medicine Pricing Works in 2026,” May 2026, referencing the CMT benchmark).

On the other end of the price scale is concierge medicine’s distant membership-medicine cousin, direct primary care. This familial but distinct subscription-based healthcare delivery model typically does not bill insurance at all and is usually considerably less expensive: a 2026 pricing index covering more than 2,780 DPC providers nationally found a national average of $92 a month and a median of $80 a month (Connectedly Health, “DPC Pricing Index by State,” February 2026), a figure roughly consistent with the Direct Primary Care Alliance’s 2026 physician survey, which found an average of $98.46 a month (cited in Medical Economics, “Five surprising findings about the state of direct primary care,” 2026).

Let’s also not forget the places patients also use for one-off care.

Urgent care sits outside this comparison in an important way: it is not a membership model, so there is no single annual figure to report. A 2026 survey of self-pay pricing across urgent care websites found simple to moderate visits typically cost $145 to $250 in cash, with complex visits involving imaging or procedures running $250 to $530 or more (Mira Health, “Urgent Care Visit Cost With and Without Insurance,” July 2026). For a patient who visits urgent care once or twice a year, annual spending in the range of $150 to $400 is a reasonable estimate, though it should be understood as CMT’s own inference from per-visit data rather than a published annual figure.

Why GLP-1 marketing is winning the moment

The gap in spend alone between GLP-1 subscriptions and concierge medicine memberships is smaller than most people in healthcare would guess. What is not smaller, at least for now, is the gap in marketing sophistication.

GLP-1 telehealth companies have built acquisition systems, not just advertising campaigns. Industry benchmarking for telehealth patient acquisition in 2026 put the cost to acquire a single paying GLP-1 patient at $150 to $250, a figure that holds up financially because the lifetime value of a subscribing patient, estimated at $600 to $2,000, comfortably exceeds it (ClinicAds, “Telehealth Marketing in 2026: The Complete Guide to Compliant, Profitable Patient Acquisition,” July 2026). That spending has shown up at scale on television: GLP-1 medications accounted for $360.9 million, or 35.7 percent, of the top ten prescription drug categories’ linear television ad spend in the first half of 2025, according to data from iSpot.tv reported by EMARKETER (“GLP-1 drugs dominate prescription TV ad spend,” 2025). That spending later fell sharply, down 71 percent year over year by mid-2026, as compounded GLP-1 marketing came under regulatory pressure (EMARKETER, “Pharma linear TV ad decline in H1 driven by steep GLP-1 spending cuts,” July 2026).

That regulatory pressure is worth naming plainly and carefully, because how we name it matters. The FDA sent 30 warning letters to telehealth companies marketing compounded GLP-1 products in March 2026 alone, alleging that promotional materials blurred the line between FDA-approved medications and unapproved compounded versions (Foley & Lardner LLP, “GLP-1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters,” March 2026). A second coordinated wave followed in June 2026, with 25 more warning letters issued over allegedly false or misleading claims (Sheppard Mullin, “FDA’s Focus Returns to Compounding and Telehealth,” June 2026). Total warning letter volume addressing compounded GLP-1 and related product claims has exceeded 55 since the FDA’s enforcement push began in September 2025 (Target Patients MD, “GLP-1 Provider Marketing That Works Right Now,” May 2026).

To be clear about what this section is and is not saying: this is not a claim that GLP-1 medications are unsafe, that the companies who received warning letters are acting in bad faith, or that concierge medicine offers a clinical alternative to them. It is a factual account of public FDA enforcement activity, reported the same way any trade publication would report it. What it suggests is narrower and more useful: a meaningful share of the marketing built around this category has drawn regulatory attention, and patients are increasingly capable of telling the difference between a confident ad and a credible one, in any category, including this one, concierge and membership medicine as a whole.

The patient/customer demographic overlap nobody in concierge medicine has named

The single most useful number in this research is not a price. It is an age.

A KFF Health Tracking Poll fielded in late October and early November 2025 found that current GLP-1 use is highest among adults ages 50 to 64, at 22 percent, compared with 11 percent for adults 30 to 49, 9 percent for adults 65 and older, and just 4 percent for adults 18 to 29 (KFF, “Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition,” November 14, 2025). A separate, larger academic survey from the RAND Corporation, fielded through its American Life Panel with nearly 8,800 respondents, reached a similar conclusion: use peaks between ages 50 and 64, and drops by more than half after age 65, a pattern researchers linked to Medicare’s lack of coverage for medications prescribed specifically for weight loss (RAND Corporation, “New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States,” August 2025).

Concierge medicine’s own patient base typically skews toward the identical age range. Industry research summarized in a 2026 concierge medicine market report found that roughly two-thirds of concierge medicine patients are age 55 and older, a pattern the report attributes to the higher prevalence of chronic conditions requiring continuous management in that age group (cited via Concierge MD Finder, “U.S. Concierge Medicine Market Report 2026,” May 2026).

Direct primary care, once again, draws a different, generally younger crowd: an industry analysis found that working-age adults 18 to 64 and their families represent the largest DPC consumer segment (Straits Research, “Direct Primary Care Market Size” industry report, July 2025), a distinction also noted by researchers at Drexel University’s Dornsife School of Public Health, whose 2024 study in the Annals of Family Medicine found that concierge practices tend to serve a more affluent, more heavily insured population than direct primary care practices, which serve a broader range of patients (Drexel News Blog, “Q+A: Is the Growth of Direct Primary Care Expanding Health Care Access Where It’s Needed Most?,” November 2024).

Urgent care use, by contrast, is nearly flat across age groups. A 2024 CDC data brief found that 28.5 percent of children ages 0 to 17 and 28.9 percent of adults 18 to 64 had at least one urgent care visit in the past year, compared with 21.9 percent of adults 65 and older (CDC/National Center for Health Statistics, Data Brief No. 562, “Urgent Care Center and Retail Health Clinic Use: United States, 2024”). Urgent care does not have a demographic center of gravity the way GLP-1 use and concierge medicine both do.

Put plainly: the age group most actively spending on GLP-1 medications and the age group that makes up the core of the concierge medicine patient base are the same age group. That is worth paying attention to. It is evidence that the 50-to-64-year-old patient is already comfortable paying monthly or annually, out of pocket, for a health outcome they believe in. Concierge medicine does not need to create that willingness to pay. It [membership medicine as a whole] needs to make the case for why that spending also belongs with a physician who knows the patient’s full history, not instead of any treatment a patient and their doctor decide is right for them, but alongside it.

What this means for concierge medicine’s marketing strategy in the years ahead

Lead with the problem, not the amenity list. GLP-1 advertising succeeds in part because its promise fits in one sentence: take this, see a visible result within weeks. Concierge medicine marketing more often opens with a list of services, same-day appointments, extended visit times, direct physician access, before ever naming the problem those services solve. Naming the failure of the fifteen-minute visit, the physician who does not know a patient’s full history, the warning sign missed for lack of time, gives the amenities somewhere to land.

“GLP-1 marketing didn’t succeed because it was flashy. It succeeded because it made one promise and kept it visible every month. Concierge medicine has a better product and a harder job: explaining a relationship instead of selling a result.”

Build a system, not a single campaign. The $150 to $250 acquisition cost that makes GLP-1 telehealth advertising profitable only works because it sits inside a full funnel: educational content, a low-friction next step, and a subscription structure that retains the patient without ongoing manual outreach. A concierge practice that wants comparable results needs the same infrastructure, a referral and content system built to run consistently, not a single seasonal ad push.

Be the trusted second opinion, not the competitor. Every FDA enforcement wave against overstated GLP-1 marketing claims is also a moment when patients are asking harder questions about who they can trust with their health decisions generally. Concierge medicine is not a treatment alternative to any prescription medication, and it should never be marketed as one. What it can be is the physician relationship a patient turns to for an honest, unhurried conversation about any treatment they’re considering, GLP-1 or otherwise. That’s a credibility opportunity concierge medicine can claim on its own terms, without disparaging any other model or product, and without implying a clinical alternative it does not offer.

“Fifty to sixty-four is the peak buyer for GLP-1s and the center of the concierge medicine patient base. ,” said Michael Tetreault, CMT’s Editor-in-Chief. “That’s not a coincidence, it’s a signal about who is actively investing in their own longevity right now.”

The bottom line

That is the strategic question this data leaves concierge medicine with. The spending is already happening. The patient is already in the market. The opportunity is not to compete with GLP-1 medications, but to learn from their marketing and advertising approach and maybe, be the clearer, better-earned answer for the patient already proving, with real money, that they are ready to invest in their own care.

Disclaimer: This article is for informational and editorial purposes. It does not constitute medical, legal, financial, or accounting advice, and it takes no position on the clinical use, safety, or efficacy of GLP-1 medications or any other prescription treatment. Concierge medicine as described here, is a healthcare membership business model. It is not a treatment, and it should not be marketed or described as an alternative or substitute for any medication a patient and their physician have determined is appropriate. Physicians and practices using any messaging from this article in their own marketing are responsible for ensuring compliance with FTC truth-in-advertising standards and their state medical board’s advertising rules, including avoiding any claim, direct or implied, that concierge membership treats, replaces, or competes with a specific medication or clinical intervention. Figures labeled as estimates reflect Concierge Medicine Today’s own analysis of published per-unit data and are identified as such throughout. Readers should consult a licensed physician, attorney, or financial advisor for guidance specific to their situation.

Sources

1. glpchart.com. “GLP-1 Telehealth Price Report 2026.” 2026.
2. GLP-1 Telemedicine. “The Real Cost of Telehealth GLP-1 Programs in 2026: Subscription Fees, Hidden Charges, and What You’re Actually Paying For.” 2026.
3. Chronos Body Health & Wellness. “The Real Cost of GLP-1 Weight Loss Medications in 2026: What You Should Know Before You Start.” April 14, 2026.
4. Concierge Medicine Today. 2026 Industry Pricing Benchmark. 2026. (cited via Concierge MD Finder, “How Concierge Medicine Pricing Works in 2026: A Real Cost Breakdown,” May 30, 2026)
5. Connectedly Health. “DPC Pricing Index by State (2026): Direct Primary Care Costs.” February 15, 2026.
6. Medical Economics. “Five surprising findings about the state of direct primary care,” citing the Direct Primary Care Alliance 2026 physician survey. 2026.
7. Mira Health (talktomira.com). “Urgent Care Visit Cost With and Without Insurance (2026 Update).” July 8, 2026.
8. ClinicAds. “Telehealth Marketing in 2026: The Complete Guide to Compliant, Profitable Patient Acquisition.” July 17, 2026.
9. EMARKETER. “GLP-1 drugs dominate prescription TV ad spend,” citing iSpot.tv data. 2025.
10. EMARKETER. “Pharma linear TV ad decline in H1 driven by steep GLP-1 spending cuts.” July 16, 2026.
11. Foley & Lardner LLP. “GLP-1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters.” March 12, 2026.
12. Sheppard Mullin. “FDA’s Focus Returns to Compounding and Telehealth: Another Wave of Warning Letters.” June 18, 2026.
13. Target Patients MD. “GLP-1 Provider Marketing That Works Right Now.” May 12, 2026.
14. KFF. “Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford.” November 14, 2025.
15. RAND Corporation. “New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States.” August 6, 2025.
16. Concierge MD Finder. “U.S. Concierge Medicine Market Report 2026: 2,601 Practices, DPC vs Traditional, Pricing,” citing the Concierge Medicine 2026-2030 industry report. May 30, 2026.
17. Straits Research. “Direct Primary Care Market Size, Top Share, Demand” industry report. July 21, 2025.
18. Drexel News Blog. “Q+A: Is the Growth of Direct Primary Care Expanding Health Care Access Where It’s Needed Most?,” citing Goldstein et al., Annals of Family Medicine. November 26, 2024.
19. Centers for Disease Control and Prevention, National Center for Health Statistics. “Urgent Care Center and Retail Health Clinic Use: United States, 2024.” NCHS Data Brief No. 562.
20. American Academy of Private Physicians (AAPP). 2026 concierge physician count estimate. (cited via Concierge MD Finder, “How Concierge Medicine Pricing Works in 2026,” May 30, 2026)